MAIA Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $65.05M
- P/E (TTM)
- –
- Dividend yield
- –
About MAIA Biotechnology
Pharmaceutical Preparations, SIC 2834
MAIA Biotechnology, Inc. is a clinical-stage biotechnology entity engaged in the research, development, and advancement of targeted oncology treatments. The enterprise primarily focuses on investigational therapies targeting telomeres and cancer cell processes to combat complex malignancies. Its therapeutic pipeline includes clinical and technological development centered on THIO (ateganosine), aimed at addressing severe oncological conditions for patients with advanced cancers. The enterprise coordinates research activities alongside collaboration and licensing agreements established with research institutions and industry partners.
The organization conducts administrative, research, and regulatory activities with domestic jurisdictions in the United States as well as foreign authorities, such as the Australian Taxation Office. MAIA Biotechnology, Inc. maintains its principal executive offices in Chicago, Illinois.
Summary of the business section of MAIA Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MAIA Biotechnology, Inc.
- Founded
- 2018
- Headquarters
- Chicago, IL
- Address
- 444 West Lake Street, Suite 1700 60606
- Phone
- (312) 416-8592
- Website
- maiabiotech.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Charlotte, North Carolina
Stock & identifiers
- Ticker
- MAIA
- Exchange
- NYSE
- IPO date
- Jul 29, 2022
- Shares outstanding
- 61M, Aug 10, 2026
- Public float
- $48.95M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1878313
- CUSIP
- 552641102
- ISIN
- US5526411021
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vlad Vitoc | Chief Executive Officer, Director | 1,259,221 |
| Sergei Gryaznov | Chief Scientific Officer | 46,511 |
| Jeffrey C. Himmelreich | Head of Finance | – |
| Ramiro Guerrero | Director | 773,296 |
| Stan Smith | Director | 1,519,178 |
| Cristian Luput | Director | 437,628 |
| Jean-Manasse Theagene | Director | – |
| Ngar Yee Louie | Director | 1,248,888 |
| Steven M. Chaouki | Director | 151,873 |
Employees
Headcount reported in annual reports
“of December 31, 2025, we had a total of 13 full-time employees which includes one employee employed by our Romanian subsidiary.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 15, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 22, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 27, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |